A carregar...
No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a
BACKGROUND: No evidence of disease activity (NEDA; defined as no 12-week confirmed disability progression, no protocol-defined relapses, no new/enlarging T2 lesions and no T1 gadolinium-enhancing lesions) using a fixed-study entry baseline is commonly used as a treatment outcome in multiple sclerosi...
Na minha lista:
Publicado no: | Mult Scler J Exp Transl Clin |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , |
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
SAGE Publications
2018
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5858626/ https://ncbi.nlm.nih.gov/pubmed/29568544 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2055217318760642 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|